View ValuationXtalPi Holdings 将来の成長Future 基準チェック /56XtalPi Holdings利益と収益がそれぞれ年間62.4%と26.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に6% 62.4%なると予測されています。主要情報62.4%収益成長率62.40%EPS成長率Life Sciences 収益成長17.6%収益成長率26.4%将来の株主資本利益率5.98%アナリストカバレッジLow最終更新日30 Mar 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 05Xtalpi and Pharmaengine Achieve Enrollment Milestone for Pep08 and Initiate Second Synthetic Lethality ProgramXtalPi (2228.HK), an AI- and robotics-powered innovation platform, announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO). PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism. PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi's ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program's steady clinical advancement. Leveraging XtalPi's integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile. Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine's deep oncology expertise with XtalPi's AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space. Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4,200 million to $17,600 million by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1,000 million, further underscoring the immense clinical value and commercial appetite for this category. The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi's AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform's evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.お知らせ • Apr 19XtalPi Holdings Limited, Annual General Meeting, May 20, 2026XtalPi Holdings Limited, Annual General Meeting, May 20, 2026, at 15:00 China Standard Time. Location: multi-functional meeting room, 3/f, second phase, of the international biomedical industrial park, no. 2 hongliu road, futian district, shenzhen Chinaお知らせ • Mar 13XtalPi Holdings Limited to Report Fiscal Year 2025 Results on Mar 25, 2026XtalPi Holdings Limited announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 25, 2026お知らせ • Sep 09Xtalpi Inc. Announces Pep08 Receives Regulatory Clearances to Initiate Phase 1 Clinical Trials in Solid TumorXtalPi Inc. has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors. Approvals include Australia'sHuman Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authority of the Taiwan region (TFDA). This milestone triggered a payment to XtalPi under the partnership agreement. PRMT5 (Protein Arginine Methyltransferase 5) is a validated synthetic lethality target in tumors harboring homozygous MTAP deletion, which is related to poor prognosis and present in 10-15% of human cancers, including small cell lung cancer (NSCLC), mesothelioma, pancreatic cancer, glioblastoma multiforme (GBM), head and neck cancer, esophageal cancer, and bladder cancer. While PRMT5 inhibition offers a potent mechanism for targeted therapy, first-generation inhibitors face significant challenges in selectivity, resulting in dose-limiting toxicities and unmet medical needs. Leveraging its integrated drug discovery platform that combines quantum physics, AI, and large-scale robotic experiments, XtalPi partnered with PharmaEngine's scientific team to conduct de novo drug design. The AI platform generated a multi-million compound library for PRMT5, identifying novel lead series with exceptional potential and selectivity. Following iterative optimization through quantum physics and AI-powered ADMET screening, PEP08 emerged as the preclinical candidate (PCC) and advanced through IND-enabling studies by PharmaEngine. As a second-generation PRMT5 inhibitor with a novel scaffold, PEP08 demonstrates superior activity and selectivity. Its MTA-cooperative binding mode stabilizes a ternary complex with PRMT5, enabling highly selective target inhibition. This mechanism drives potent synthetic lethality efficacy against MTAP-deleted tumor cells while minimizing off-target effects on normal cells, highlighting significant therapeutic potential. Preclinical studies revealed PEP08's markedly improved safety profile compared to first-generation PRMT5 inhibitors, alongside favorable blood-brain barrier penetration and overall developability characteristics. The compound achieved robust in vivo efficacy across multiple animal models. Compared to other clinical-stage second-generation candidates, PEP08 exhibits potential best-in-class properties and compelling combination therapy opportunities. PharmaEngine presented these findings at the 2025 American Association for Cancer Research (AACR) Annual Meeting. PEP08's successful regulatory clearance and milestone achievement underscore XtalPi's platform-driven innovation capabilities and mark a pivotal advancement in its partnership with PharmaEngine. XtalPi remains committed to empowering partners to discover novel drug candidates addressing complex targets, accelerate the development of competitive pipeline projects, and deliver transformative medicines to patients worldwide.お知らせ • Sep 04XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listingお知らせ • Aug 30XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listingお知らせ • Aug 15XtalPi Holdings Limited to Report First Half, 2025 Results on Aug 27, 2025XtalPi Holdings Limited announced that they will report first half, 2025 results on Aug 27, 2025お知らせ • Jun 13XtalPi Holdings Limited (SEHK:2228) acquired Liverpool ChiroChem Limited.XtalPi Holdings Limited (SEHK:2228) acquired Liverpool ChiroChem Limited on June 12, 2025. XtalPi Holdings Limited (SEHK:2228) completed the acquisition of Liverpool ChiroChem Limited on June 12, 2025.業績と収益の成長予測OTCPK:QNTP.F - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,736588N/A804212/31/20271,336332N/A110312/31/202687838N/A454212/31/2025803124-247-165N/A9/30/2025742-37-365-292N/A6/30/2025681-197-483-418N/A3/31/2025474-857-512-448N/A12/31/2024266-1,517-541-479N/A9/30/2024232-2,027-612-523N/A6/30/2024197-2,538-684-568N/A3/31/2024186-2,226-691-568N/A12/31/2023174-1,914-698-568N/A12/31/2022133-1,439-628-429N/A12/31/202163-2,137-417-254N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: QNTP.Fの予測収益成長率 (年間62.4% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: QNTP.Fの収益 ( 62.4% ) はUS市場 ( 16.8% ) よりも速いペースで成長すると予測されています。高成長収益: QNTP.Fの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: QNTP.Fの収益 ( 26.4% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: QNTP.Fの収益 ( 26.4% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: QNTP.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 6 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 16:40終値2026/05/15 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋XtalPi Holdings Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Yu WuCMB International Securities LimitedWing-Tai NgDeutsche BankYue-Kwong LuiJefferies LLC2 その他のアナリストを表示
お知らせ • May 05Xtalpi and Pharmaengine Achieve Enrollment Milestone for Pep08 and Initiate Second Synthetic Lethality ProgramXtalPi (2228.HK), an AI- and robotics-powered innovation platform, announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO). PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism. PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi's ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program's steady clinical advancement. Leveraging XtalPi's integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile. Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine's deep oncology expertise with XtalPi's AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space. Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4,200 million to $17,600 million by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1,000 million, further underscoring the immense clinical value and commercial appetite for this category. The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi's AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform's evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.
お知らせ • Apr 19XtalPi Holdings Limited, Annual General Meeting, May 20, 2026XtalPi Holdings Limited, Annual General Meeting, May 20, 2026, at 15:00 China Standard Time. Location: multi-functional meeting room, 3/f, second phase, of the international biomedical industrial park, no. 2 hongliu road, futian district, shenzhen China
お知らせ • Mar 13XtalPi Holdings Limited to Report Fiscal Year 2025 Results on Mar 25, 2026XtalPi Holdings Limited announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 25, 2026
お知らせ • Sep 09Xtalpi Inc. Announces Pep08 Receives Regulatory Clearances to Initiate Phase 1 Clinical Trials in Solid TumorXtalPi Inc. has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors. Approvals include Australia'sHuman Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authority of the Taiwan region (TFDA). This milestone triggered a payment to XtalPi under the partnership agreement. PRMT5 (Protein Arginine Methyltransferase 5) is a validated synthetic lethality target in tumors harboring homozygous MTAP deletion, which is related to poor prognosis and present in 10-15% of human cancers, including small cell lung cancer (NSCLC), mesothelioma, pancreatic cancer, glioblastoma multiforme (GBM), head and neck cancer, esophageal cancer, and bladder cancer. While PRMT5 inhibition offers a potent mechanism for targeted therapy, first-generation inhibitors face significant challenges in selectivity, resulting in dose-limiting toxicities and unmet medical needs. Leveraging its integrated drug discovery platform that combines quantum physics, AI, and large-scale robotic experiments, XtalPi partnered with PharmaEngine's scientific team to conduct de novo drug design. The AI platform generated a multi-million compound library for PRMT5, identifying novel lead series with exceptional potential and selectivity. Following iterative optimization through quantum physics and AI-powered ADMET screening, PEP08 emerged as the preclinical candidate (PCC) and advanced through IND-enabling studies by PharmaEngine. As a second-generation PRMT5 inhibitor with a novel scaffold, PEP08 demonstrates superior activity and selectivity. Its MTA-cooperative binding mode stabilizes a ternary complex with PRMT5, enabling highly selective target inhibition. This mechanism drives potent synthetic lethality efficacy against MTAP-deleted tumor cells while minimizing off-target effects on normal cells, highlighting significant therapeutic potential. Preclinical studies revealed PEP08's markedly improved safety profile compared to first-generation PRMT5 inhibitors, alongside favorable blood-brain barrier penetration and overall developability characteristics. The compound achieved robust in vivo efficacy across multiple animal models. Compared to other clinical-stage second-generation candidates, PEP08 exhibits potential best-in-class properties and compelling combination therapy opportunities. PharmaEngine presented these findings at the 2025 American Association for Cancer Research (AACR) Annual Meeting. PEP08's successful regulatory clearance and milestone achievement underscore XtalPi's platform-driven innovation capabilities and mark a pivotal advancement in its partnership with PharmaEngine. XtalPi remains committed to empowering partners to discover novel drug candidates addressing complex targets, accelerate the development of competitive pipeline projects, and deliver transformative medicines to patients worldwide.
お知らせ • Sep 04XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 30XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 15XtalPi Holdings Limited to Report First Half, 2025 Results on Aug 27, 2025XtalPi Holdings Limited announced that they will report first half, 2025 results on Aug 27, 2025
お知らせ • Jun 13XtalPi Holdings Limited (SEHK:2228) acquired Liverpool ChiroChem Limited.XtalPi Holdings Limited (SEHK:2228) acquired Liverpool ChiroChem Limited on June 12, 2025. XtalPi Holdings Limited (SEHK:2228) completed the acquisition of Liverpool ChiroChem Limited on June 12, 2025.